Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer

Tin O o Khor, Francisco Fuentes, Limin Shu, Ximena Paredes-Gonzalez, Anne Y uqing Yang, Yue Liu, Dominic J. Smiraglia, S Yegnasubramanian, William G Nelson, Ah Ng T ony Kong

Research output: Contribution to journalArticle

Abstract

Epigenetic control of NRF2, a master regulator of many critical antioxidative stress defense genes in human prostate cancer (CaP), is unknown. Our previous animal study found decreased Nrf2 expression through promoter CpG methylation/histone modifications during prostate cancer progression in TRAMP mice. In this study, we evaluated CpG methylation of human NRF2 promoter in 27 clinical prostate cancer samples and in LNCaP cells using MAQMA analysis and bisulfite genomic DNA sequencing. Prostate cancer tissue microarray (TMA) containing normal and prostate cancer tissues was studied by immunohistochemistry. Luciferase reporter assay using specific human NRF2 DNA promoter segments and chromatin immunoprecipitation (ChIP) assay against histone modifying proteins were performed in LNCaP cells. Three specific CpG sites in the NRF2 promoter were found to be hypermethylated in clinical prostate cancer samples (BPH

Original languageEnglish (US)
Pages (from-to)1186-1197
Number of pages12
JournalCancer Prevention Research
Volume7
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

DNA Methylation
Epigenomics
Prostatic Neoplasms
Methylation
Histone Code
Chromatin Immunoprecipitation
Luciferases
DNA Sequence Analysis
Histones
Immunohistochemistry
DNA
Genes
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Khor, T. O. O., Fuentes, F., Shu, L., Paredes-Gonzalez, X., Yang, A. Y. U., Liu, Y., ... Kong, A. N. T. O. (2014). Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer. Cancer Prevention Research, 7(12), 1186-1197. https://doi.org/10.1158/1940-6207.CAPR-14-0127

Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer. / Khor, Tin O o; Fuentes, Francisco; Shu, Limin; Paredes-Gonzalez, Ximena; Yang, Anne Y uqing; Liu, Yue; Smiraglia, Dominic J.; Yegnasubramanian, S; Nelson, William G; Kong, Ah Ng T ony.

In: Cancer Prevention Research, Vol. 7, No. 12, 01.12.2014, p. 1186-1197.

Research output: Contribution to journalArticle

Khor, TOO, Fuentes, F, Shu, L, Paredes-Gonzalez, X, Yang, AYU, Liu, Y, Smiraglia, DJ, Yegnasubramanian, S, Nelson, WG & Kong, ANTO 2014, 'Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer', Cancer Prevention Research, vol. 7, no. 12, pp. 1186-1197. https://doi.org/10.1158/1940-6207.CAPR-14-0127
Khor, Tin O o ; Fuentes, Francisco ; Shu, Limin ; Paredes-Gonzalez, Ximena ; Yang, Anne Y uqing ; Liu, Yue ; Smiraglia, Dominic J. ; Yegnasubramanian, S ; Nelson, William G ; Kong, Ah Ng T ony. / Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer. In: Cancer Prevention Research. 2014 ; Vol. 7, No. 12. pp. 1186-1197.
@article{de4e88c46dc2478894a7d2d159edf40d,
title = "Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer",
abstract = "Epigenetic control of NRF2, a master regulator of many critical antioxidative stress defense genes in human prostate cancer (CaP), is unknown. Our previous animal study found decreased Nrf2 expression through promoter CpG methylation/histone modifications during prostate cancer progression in TRAMP mice. In this study, we evaluated CpG methylation of human NRF2 promoter in 27 clinical prostate cancer samples and in LNCaP cells using MAQMA analysis and bisulfite genomic DNA sequencing. Prostate cancer tissue microarray (TMA) containing normal and prostate cancer tissues was studied by immunohistochemistry. Luciferase reporter assay using specific human NRF2 DNA promoter segments and chromatin immunoprecipitation (ChIP) assay against histone modifying proteins were performed in LNCaP cells. Three specific CpG sites in the NRF2 promoter were found to be hypermethylated in clinical prostate cancer samples (BPH",
author = "Khor, {Tin O o} and Francisco Fuentes and Limin Shu and Ximena Paredes-Gonzalez and Yang, {Anne Y uqing} and Yue Liu and Smiraglia, {Dominic J.} and S Yegnasubramanian and Nelson, {William G} and Kong, {Ah Ng T ony}",
year = "2014",
month = "12",
day = "1",
doi = "10.1158/1940-6207.CAPR-14-0127",
language = "English (US)",
volume = "7",
pages = "1186--1197",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer

AU - Khor, Tin O o

AU - Fuentes, Francisco

AU - Shu, Limin

AU - Paredes-Gonzalez, Ximena

AU - Yang, Anne Y uqing

AU - Liu, Yue

AU - Smiraglia, Dominic J.

AU - Yegnasubramanian, S

AU - Nelson, William G

AU - Kong, Ah Ng T ony

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Epigenetic control of NRF2, a master regulator of many critical antioxidative stress defense genes in human prostate cancer (CaP), is unknown. Our previous animal study found decreased Nrf2 expression through promoter CpG methylation/histone modifications during prostate cancer progression in TRAMP mice. In this study, we evaluated CpG methylation of human NRF2 promoter in 27 clinical prostate cancer samples and in LNCaP cells using MAQMA analysis and bisulfite genomic DNA sequencing. Prostate cancer tissue microarray (TMA) containing normal and prostate cancer tissues was studied by immunohistochemistry. Luciferase reporter assay using specific human NRF2 DNA promoter segments and chromatin immunoprecipitation (ChIP) assay against histone modifying proteins were performed in LNCaP cells. Three specific CpG sites in the NRF2 promoter were found to be hypermethylated in clinical prostate cancer samples (BPH

AB - Epigenetic control of NRF2, a master regulator of many critical antioxidative stress defense genes in human prostate cancer (CaP), is unknown. Our previous animal study found decreased Nrf2 expression through promoter CpG methylation/histone modifications during prostate cancer progression in TRAMP mice. In this study, we evaluated CpG methylation of human NRF2 promoter in 27 clinical prostate cancer samples and in LNCaP cells using MAQMA analysis and bisulfite genomic DNA sequencing. Prostate cancer tissue microarray (TMA) containing normal and prostate cancer tissues was studied by immunohistochemistry. Luciferase reporter assay using specific human NRF2 DNA promoter segments and chromatin immunoprecipitation (ChIP) assay against histone modifying proteins were performed in LNCaP cells. Three specific CpG sites in the NRF2 promoter were found to be hypermethylated in clinical prostate cancer samples (BPH

UR - http://www.scopus.com/inward/record.url?scp=84964698213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964698213&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-14-0127

DO - 10.1158/1940-6207.CAPR-14-0127

M3 - Article

C2 - 25266896

AN - SCOPUS:84919346523

VL - 7

SP - 1186

EP - 1197

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 12

ER -